Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04250506
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT04225078
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Economic Evaluation of New MDR TB Regimens
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 73
- Registration Number
- NCT04207112
- Locations
- 🇿🇦
THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa
🇿🇦King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇧🇾Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
Vigamox Treatment for Ocular Graft-Versus-Host Disease
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT04204122
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 26
- Registration Number
- NCT04179500
- Locations
- 🇿🇦
CHRU, Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
🇿🇦Isango Lethemba TB Research Unit Empilweni TB Hospital, Port Elizabeth, South Africa
🇿🇦The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 70
- Registration Number
- NCT04175808
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 54
- Registration Number
- NCT04126343
- Locations
- 🇬🇧
Up0050 001, London, United Kingdom
PRACTECAL-PKPD Sub Study
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 240
- Registration Number
- NCT04081077
- Locations
- 🇧🇾
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
🇿🇦King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇿🇦THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 55
- Registration Number
- NCT04019652
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Entasis Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT03985410
- Locations
- 🇺🇸
Pharmaron Clinical Pharmacology Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.